Even if the legislative initiatives in both Europe and the USA emphasizes the importance of large clinical trial in children, prioritizing the medicines to be studied on the basis of children's needs [ 45 ], differences between countries in drug licensing procedures, and occasionally in the approach towards certain therapeutic problems, may be quite significant [ 30 ].
← all excerpts
Ocular medicines in children: the regulatory situation related to clinical research.
1
—
—